Trastuzumab Clinical Trials
71 recruitingDrug
Phase 243Phase 317Phase 116Phase 45
Showing 1–20 of 71 trials
Recruiting
Phase 2
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Esophageal CancerGastric AdenocarcinomaHER2 Gene Mutation
Memorial Sloan Kettering Cancer Center49 enrolled10 locationsNCT06123338
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 1Phase 2
Elacestrant in Advanced Triple Positive Breast Cancer
ER Positive, HER2 Positive Breast Cancer
NYU Langone Health50 enrolled1 locationNCT07612215
Recruiting
Phase 1Phase 2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC81 enrolled18 locationsNCT06686394
Recruiting
Phase 3
Personalized Medicine for Advanced Biliary Cancer Patients
Biliary Tract Neoplasms
UNICANCER800 enrolled69 locationsNCT05615818
Recruiting
Phase 2
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8
University of Washington25 enrolled1 locationNCT04329065
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Gastric Cancer
AstraZeneca450 enrolled100 locationsNCT04379596
Recruiting
Phase 2
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Rectal CancerRectal AdenocarcinomaAdenocarcinoma of the Rectum+2 more
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT05672524
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled289 locationsNCT06764875
Recruiting
Phase 2Phase 3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer
Hoffmann-La Roche650 enrolled4 locationsNCT07413939
Recruiting
Phase 2
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Metastatic Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8Stage IV Major Salivary Gland Cancer AJCC v8+2 more
NRG Oncology146 enrolled150 locationsNCT05408845
Recruiting
Phase 2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled26 locationsNCT07102381
Recruiting
Phase 1
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
Healthy Participants
Genentech, Inc.312 enrolled4 locationsNCT07214766
Recruiting
Phase 2
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Colorectal Cancer MetastaticAdvanced Colorectal Cancer
Suzhou Teligene Ltd.80 enrolled1 locationNCT06589830
Recruiting
Phase 1
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Esophageal CancerGastric CancerGastroesophageal-junction Cancer+2 more
Washington University School of Medicine42 enrolled1 locationNCT05187182
Recruiting
Phase 2
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
HER2-positive Early-stage Breast Cancer
Rutgers, The State University of New Jersey50 enrolled7 locationsNCT07402473
Recruiting
Phase 2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Breast Cancer Metastatic
ALX Oncology Inc.120 enrolled32 locationsNCT07007559
Recruiting
Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Breast CancerColorectal, CancerOvarian Cancer+3 more
Fate Therapeutics113 enrolled5 locationsNCT07216105